The brains of Alzheimer's mice treated with the compound RU-505 showed less inflammation and improved blood flow than those of untreated mice. The treated mice also performed better on memory tests, researchers report. For more than a decade, potential Alzheimer's drugs have targeted amyloid-², but, in clinical trials, they have either failed to slow the progression of the disease or caused serious side effects. However, by targeting the protein's ability to bind to a clotting agent in blood, th...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/k...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/k...